Stemline Therapeutics (NASDAQ:STML) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.08, Fidelity Earnings reports. The business had revenue of $13.33 million during the quarter, compared to the consensus estimate of $13.40 million.
Shares of NASDAQ:STML traded down $1.19 during trading hours on Friday, hitting $9.25. The stock had a trading volume of 2,655,100 shares, compared to its average volume of 625,907. The stock’s fifty day simple moving average is $9.85 and its 200 day simple moving average is $12.94. Stemline Therapeutics has a 1-year low of $7.82 and a 1-year high of $18.22. The firm has a market capitalization of $486.37 million, a price-to-earnings ratio of -3.09 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.57 and a current ratio of 4.71.
STML has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Stemline Therapeutics in a report on Monday, September 30th. Cowen restated a “buy” rating on shares of Stemline Therapeutics in a research note on Wednesday, September 18th. BidaskClub upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. Wedbush upgraded shares of Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Friday, August 2nd. Finally, ValuEngine lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 11th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $22.83.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Featured Article: Treasury Bonds
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.